C
Cerus Corporation (CERS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
$1.86
-0.12 (-6.30%)
Market Cap: $400.88M
Last updated: Nov 17, 2026 at 11:04 AM ET
Cerus Corporation (CERS) Valuation Multiples
Cerus (CERS) trades at 1.6x sales and 5.0x book value. Its P/S of 1.6x is below its 5-year median of 2.0x.
Current Multiples
Its enterprise value is 284.0x its EBITDA. Its free cash flow yield is 0.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 1.6x |
| Price to book | 5.0x |
| EV/EBITDA | 284.0x |
| Price to FCF | 759.3x |
| EV/FCF | 854.4x |
| PEG | N/A |
| FCF yield | 0.1% |
Historical Medians
Against its 10-year medians, its P/S is 73.3% below 6.0x and its P/B is 42.5% below 8.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.6x | 2.0x | 6.0x |
| P/B | 5.0x | 6.8x | 8.7x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.4x in 2024 to 11.3x in 2016.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $2.06 | 1.8x | 6.2x |
| 2024 | $1.54 | 1.4x | 5.1x |
| 2023 | $2.16 | 2.1x | 7.4x |
| 2022 | $3.65 | 3.4x | 9.6x |
| 2021 | $6.81 | 7.3x | 13.9x |
| 2020 | $6.92 | 9.9x | 11.2x |
| 2019 | $4.22 | 6.3x | 10.6x |
| 2018 | $5.07 | 8.8x | 8.2x |
| 2017 | $3.38 | 7.2x | 9.9x |
| 2016 | $4.35 | 11.3x | 7.8x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CERS
Is CERS stock overvalued?
GNG's valuation label for CERS is Undervalued.
What is CERS's price to sales ratio?
Cerus has a price to sales ratio of 1.6x.
CERS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts